A Phase III, Randomised, Double -Blind, Active-controlled Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination with Dapagliflozin Compared with Dapagliflozin Alone on Chronic Kidney Disease (CKD) Progression in Participants with CKD and High Blood Pressure

drug protocol number

D6972C00003

drug sponsor

AstraZeneca

drug study

Baxdrostat

drug trial site

King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Specialist Hospital (Dammam)

drug status

Ongoing

drug phase